A&R:UBE2L3/YDJC自身免疫性疾病风险单倍型的变异通过调节CCCTC结合因子和YY1结合增加UBE2L3表达

2022-01-24 MedSci原创 MedSci原创

UBE2L3/YDJC自身免疫风险单倍型通过加强YY1介导的UBE2L3和 YDJC启动子之间的相互作用来增加UBE2L3的表达。

     目的:跨越UBE2L3的遗传变异与UBE2L3编码的E2泛素结合酶H7 (UbcH7) 的表达增加有关,这有助于激活促炎NF-κB信号传导和增加对自身免疫性疾病的易感性。研究者进行了这项研究,以描述遗传变异如何通过UBE2L3/YDJC自身免疫风险单倍型功能来驱动超形UBE2L3表达 (超形表达:基因产物活性水平增加,或野生型基因产物的水平表达增加。)

     方法:研究者使用生物信息学分析、电泳迁移率变化分析(EMSA)和荧光素酶报告基因分析来识别和功能表征位于免疫细胞染色质可接近区域的风险变异的等位基因特异性影响。使用定量聚合酶链式反应捕获染色质构象 (3C-qPCR)、染色质免疫沉淀(ChIP)-qPCR和小干扰RNA (siRNA) 敲低对患者来源的Epstein-Barr病毒转化的UBE2L3/YDJC纯合子非风险或风险单倍型B细胞进行实验,以确定风险单倍型是否通过改变该区域的调节染色质结构来增加UBE2L3表达。

     结果:在7个优先变异中,5 个表现出等位基因特异性增加核蛋白结合亲和力和调节活性。染色体构象捕获的高通量测序结合ChIP (HiChIP) 3C-qPCR揭示了 UBE2L3启动子 (rs140490rs140491rs11089620) 和下游YDJC启动子(rs3747093) 之间的远程相互作用,这种相互作用在UBE2L3/YDJC风险单倍型增强并与风险等位基因上CCCTC结合因子(CTCF) 的丧失和YY1 结合的增加相关。通过siRNA消耗 YY1破坏了2个启动子之间的远程相互作用并降低了UBE2L3的表达。

    结论:UBE2L3/YDJC自身免疫风险单倍型通过加强YY1介导的UBE2L3 YDJC启动子之间的相互作用来增加UBE2L3的表达。 

出处:

Gopalakrishnan, J., Tessneer, K.L., Fu, Y., Pasula, S., Pelikan, R.C., Kelly, J.A., Wiley, G.B. and Gaffney, P.M. (2022), Variants on the UBE2L3/YDJC Autoimmune Disease Risk Haplotype Increase UBE2L3 Expression by Modulating CCCTC-Binding Factor and YY1 Binding. Arthritis Rheumatol, 74: 163-173. https://doi.org/10.1002/art.41925

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1968092, encodeId=3b91196809249, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Fri Apr 08 13:52:05 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796538, encodeId=8ac71e96538c2, content=<a href='/topic/show?id=b26d1806154' target=_blank style='color:#2F92EE;'>#UBE2L3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18061, encryptionId=b26d1806154, topicName=UBE2L3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 15 07:52:05 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895590, encodeId=1c70189559077, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Wed Aug 31 11:52:05 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342956, encodeId=f3181342956df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473312, encodeId=2a1514e331275, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580184, encodeId=f7f2158018419, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-04-08 wshxjq
  2. [GetPortalCommentsPageByObjectIdResponse(id=1968092, encodeId=3b91196809249, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Fri Apr 08 13:52:05 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796538, encodeId=8ac71e96538c2, content=<a href='/topic/show?id=b26d1806154' target=_blank style='color:#2F92EE;'>#UBE2L3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18061, encryptionId=b26d1806154, topicName=UBE2L3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 15 07:52:05 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895590, encodeId=1c70189559077, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Wed Aug 31 11:52:05 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342956, encodeId=f3181342956df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473312, encodeId=2a1514e331275, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580184, encodeId=f7f2158018419, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1968092, encodeId=3b91196809249, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Fri Apr 08 13:52:05 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796538, encodeId=8ac71e96538c2, content=<a href='/topic/show?id=b26d1806154' target=_blank style='color:#2F92EE;'>#UBE2L3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18061, encryptionId=b26d1806154, topicName=UBE2L3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 15 07:52:05 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895590, encodeId=1c70189559077, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Wed Aug 31 11:52:05 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342956, encodeId=f3181342956df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473312, encodeId=2a1514e331275, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580184, encodeId=f7f2158018419, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-08-31 kalseyzl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1968092, encodeId=3b91196809249, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Fri Apr 08 13:52:05 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796538, encodeId=8ac71e96538c2, content=<a href='/topic/show?id=b26d1806154' target=_blank style='color:#2F92EE;'>#UBE2L3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18061, encryptionId=b26d1806154, topicName=UBE2L3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 15 07:52:05 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895590, encodeId=1c70189559077, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Wed Aug 31 11:52:05 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342956, encodeId=f3181342956df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473312, encodeId=2a1514e331275, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580184, encodeId=f7f2158018419, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1968092, encodeId=3b91196809249, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Fri Apr 08 13:52:05 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796538, encodeId=8ac71e96538c2, content=<a href='/topic/show?id=b26d1806154' target=_blank style='color:#2F92EE;'>#UBE2L3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18061, encryptionId=b26d1806154, topicName=UBE2L3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 15 07:52:05 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895590, encodeId=1c70189559077, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Wed Aug 31 11:52:05 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342956, encodeId=f3181342956df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473312, encodeId=2a1514e331275, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580184, encodeId=f7f2158018419, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1968092, encodeId=3b91196809249, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Fri Apr 08 13:52:05 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796538, encodeId=8ac71e96538c2, content=<a href='/topic/show?id=b26d1806154' target=_blank style='color:#2F92EE;'>#UBE2L3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18061, encryptionId=b26d1806154, topicName=UBE2L3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 15 07:52:05 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895590, encodeId=1c70189559077, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Wed Aug 31 11:52:05 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342956, encodeId=f3181342956df, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473312, encodeId=2a1514e331275, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580184, encodeId=f7f2158018419, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Tue Jan 25 23:52:05 CST 2022, time=2022-01-25, status=1, ipAttribution=)]

相关资讯

女性不孕不育与自身抗体(综述摘译)

孕不育患者中,约10%的病因不明,在这些病例中自身免疫性疾病(如:系统性红斑狼疮、抗磷脂综合征等)占有一定比例。

Nat Commun:自身免疫性肺泡蛋白沉积症发病风险相关遗传决定因素

肺泡蛋白沉积症(PAP)是一种罕见的弥漫性肺部疾病,在全球中每百万人有6-7例患病。

Br J Cancer:免疫检查点阻断治疗诱导的自身免疫与转移性黑色素瘤的预后和独特的T细胞表达谱相关

免疫检查点阻断(ICB)疗法是一类通过介导T细胞活性来提高抗肿瘤免疫反应的治疗方法。

EULAR :重视风湿性免疫相关不良事件

在接受检查点抑制剂 (CPI) 治疗的癌症患者中,约有 10% 观察到风湿性和肌肉骨骼免疫相关不良事件 (irAE)。

炎症小体和儿童自身免疫性疾病有关系?

大量文献已表明基因与环境之间失调的相互作用会导致人类自身免疫性疾病。